このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Comparing Different Amounts of Vitamin D Supplementation to Preschool Children Living in Northern and Southern Sweden (Dvisum)

2016年10月31日 更新者:Torbjörn Lind、Umeå University

Vitamin D has a range of biological effects of public health relevance. Vitamin D status is assessed on levels of its metabolite 25-hydroxyvitamin D [25(OH)D], where levels < 50 nmol/L indicate insufficiency. Despite studies indicating that the vitamin D intake among Swedish children are significantly below recommendations, little is known of their vitamin D status. The investigators have recently found inadequate vitamin D status in pre-school children living in northern Sweden, especially in dark-skinned children and during the winter months despite vitamin D intakes meeting the recommendations. Overall, 25% of the light skinned and 40% of the dark skinned children had S-25(OH) D <50 nmol/L (Öhlund I, unpublished data). The aim is to examine which amount of vitamin D is needed to maintain or increase S-25(OH)D to ≥50 nmol/L among 97.5% of the participants regardless of skin color or geographic location (northern or southern Sweden). Furthermore the investigators will examine if vitamin D status affects on health markers as bone density, blood pressure, serum lipids, fatty acids, inflammatory and immunological markers and mental wellbeing.

Children aged 5-8 years living either northern (Umeå) or southern Sweden (Malmö) will be recruited to this trial during November-December 2012. They will be randomized to a vitamin D supplement of either 10 or 25 g per day, or in Malmö also placebo to be used for three months. The randomization will be stratified according to skin color (light or dark) according to a method using visual inspection and interviews of parents/guardians. The investigators will use a 2×2×2 factorial design to investigate the effects of two different doses of vitamin D (10 µg and 25 µg) in children with dark and light skin color, living in northern (Umeå) and southern (Malmö), Sweden. In order to achieve a moderate difference between groups (effect size 0.25) 20 children per group are required (power> 87%, alpha = 0.05). With an estimated dropout of 10%, a total of 220 children will be included.

At baseline, the participants will undergo blood sampling for S-25(OH)D and other biomarkers, blood pressure and anthropometrical measurements, including bone densitometry and body composition using air displacement pletysmography, and the parents will answer a questionnaire on behavioral and emotional problems in the participating child using the Child Behavior Checklist. These measurements will be repeated at follow-up in February-March 2013.

調査の概要

詳細な説明

Vitamin D has a range of biological effects of public health relevance (Prentice et al, 2008). Besides its well known role in mineralization of bone and teeth, vitamin D also play important roles in metabolic functions, the pathogenesis of certain diseases, e.g. type 1 diabetes, celiac disease, asthma and allergies, as well as in the prevention of cancer (Holick, 2008).

Vitamin D status is assessed on plasma or serum levels of its metabolite 25-hydroxyvitamin D [25(OH)D, calcidiol] as it reflects the sum of vitamin D converted in the skin through sunlight exposure and from dietary sources. Several reports advocate that levels <37 nmol/L denote severe vitamin D deficiency; levels <50 nmol/L insufficient; 50-75 nmol/L suboptimal levels and ≥75nmol/L optimal levels (Dawson-Hughes et al, 2005, Huh et al, 2008, Yetley, 2008). In children, most suggested cut-off values for adequate levels of 25(OH)D are based on the absence of rickets, increased measures of bone mineralization and maximal suppression of parathyroid hormone (PTH) levels (Greer, 2009).

The major source of vitamin D is dermal biosynthesis catalyzed by ultraviolet B sunlight (Cashman et al, 2011). However, during winter, northern Sweden has limited hours of daylight leading to reduced sun exposure. Consequently, the dietary source of vitamin D is of specific importance in this region (Brustad et al, 2007, Edvardsen et al, 2007). Fatty fish, eggs, vitamin D fortified milk and margarines are the main sources, mainly supplying the most active form D3. These are important basic foods which also contain common food allergens. Thus, children with food allergies to milk, fish, and egg can be at increased risk of vitamin D deficiency. Several dairy products are fortified with vitamin D, but in some products in the form of D2 which is not as bioactive as D3.

Skin color affects the capacity to form vitamin D3 as children with dark complexion need 5-10 times more sun exposure to generate the same amount of vitamin D3 compared to fair-skinned children, and therefore are at increased risk of vitamin D deficiency when exposure to sun is limited (Holick, 2005). Recently the recommendations on protecting the skin from sunshine to reduce the risk of skin cancer later in life has been debated as it may increase the risk of vitamin D deficiency (Stechschulte et al, 2011). Obesity in children might be another risk factor for vitamin D deficiency, since an increased proportion of available vitamin D may be stored in adipose tissue thus lowering the S-25(OH)D (Prentice, 2008).

Despite studies indicating that the vitamin D intake among Swedish children and adolescents are significantly below recommendations, little is known of their vitamin D status (Garemo et al, 2007, Enghardt et al, 2006, Öhlund et al, 2010). Furthermore there is a paucity of studies investigating vitamin D intake and status in food-allergic adolescents who may be at increased risk of vitamin D insufficiency due to strict avoidance of vitamin D containing foods.

Recently the investigators of Dvisum assessed Vitamin D status in pre-school children (n=90; mean age 54+/-7.1 mo), all living in northern Sweden (latitude 63°) and half of them with fair skin, half with darker complexion. The study group was examined first in August-September (late summer) and then the following January-February (winter). Skin type, vitamin D intake, anthropometrics, S-25(OH) D and parathyroid hormone (S-PTH) were assessed. The investigators found inadequate vitamin D status in these children living in northern Sweden, especially in dark-skinned children and during the winter despite vitamin D intakes meeting the recommendations, prompting strategies to improve intake of vitamin D in this population. Overall, 25% and 40% of the light and dark skinned had S-25(OH) D <50 nmol/L.

The aim is to examine which amount of vitamin D is needed to maintain or increase S-25(OH)D to ≥50 nmol/L among 97.5% of the participants regardless of skin color or geographic location (northern or southern Sweden). Furthermore the investigators will examine if vitamin D status affects health markers such as bone density, blood pressure, serum lipids, fatty acids and inflammatory and immunological markers and mental wellbeing.

In order to identify whether there are differences depending on the latitude within Sweden, children will be recruited both from northern Sweden (Umeå) and from southern Sweden (Malmo). As it is unclear what levels of the serological marker 25 (OH) D that affect the health of children, different markers of health will be examined before and after the intervention. Children aged 5-8 years, 50% fair-skin 50 % darker skin, in northern Sweden (Umeå) and southern Sweden (Malmö) will be included in a longitudinal, randomized trial. The children are first examined in November-December and randomized to a vitamin D supplement of either 10 or 25 g per day, to be used for three months. At the follow up in February-March all examinations will be repeated.

The investigators will use a 2 × 2 × 2 factorial design to investigate the effects of two different doses of vitamin D (10 µg and 25 µg) in children with dark and light skin color, living in northern (Umeå) and southern (Malmö), Sweden. In order to achieve a moderate difference between groups (effect size 0.25) requires 20 children per group (power>87%, alpha = 0.05). With this group size, we can see a group difference in the S-25 (OH) D of 3.75 nmol/L, S-PTH of 0.35 mmol/L and bone mineral density in the lumbar region of 0.075 g/cm2. In Skåne, but not Umeå also a placebo group will participate. With an estimated dropout of 10%, a total of 220 children will be included.

The study include sampling for analysis of S-25 (OH) D, calcium, phosphate, alkaline phosphatase (ALP), magnesium, PTH and osteocalcin, serum lipids (total cholesterol, HDL cholesterol, LDL cholesterol. ApoA1 and ApoB lipoprotein) and fatty acids as well as inflammatory and immunological markers (CRP, interleukin (IL) -1 and 2, IL-4, IL-6, I-10, Il-17, CD40 ligand, TNF and IFNγ, fibrinogen and antisecretory factor). Before sampling, the children receive a topical anesthetic (EMLA).

Measurements of blood pressure and anthropometric measurements of length, weight, waist circumference and bone densitometry (DEXA) and body composition (fat mass% and fat free mass) using a Air Displacement Plethysmography ( BOD POD) Questions about diet, vitamin supplements, foreign travel, how much time the children spend time outdoors and the use of sunscreen as well as questions about the child's health and family situation will be answered by the parents through a questionnaire. To investigate the possible association between vitamin D status and mental well-being, the investigators will use the Child Behaviour Checklist (CBCL).

This study is national with a multicultural perspective, it is expected to provide knowledge about the needs of vitamin D to prevent vitamin D deficiency. The study is also expected to provide a better understanding of association between vitamin D status and various markers of health among children.

By preventing vitamin D deficiency, poor bone development, susceptibility to infections, and perhaps prone to autoimmune diseases and cardiovascular risk factors could be reduced, and hopefully the mental well-being improved, which reduces costs to both society and the individual, and reduces unnecessary suffering of individuals.

研究の種類

介入

入学 (実際)

220

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Skåne
      • Malmö、Skåne、スウェーデン、20502
        • Department of Pediatrics, University hospital Malmö
    • Västerbotten
      • Umeå、Västerbotten、スウェーデン、90187
        • Pediatrics, Department of Clinical Sciences, Umeå University

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

5年~7年 (子)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • 5-7 years of age
  • Healthy

Exclusion Criteria:

  • Chronic illness, including coeliac disease or other chronic gastrointestinal disorders
  • Drugs that can affect bone health or vitamin D uptake
  • Cow's milk allergy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:階乗代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Umeå, vitamin D 25 microg/d, light skin
Participants with light skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
The vitamin D supplement will be provided as a milk drink taken daily.
アクティブコンパレータ:Umeå, vitamin D 10 microg/d, dark skin
Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
The vitamin D supplement will be provided as a milk drink taken daily.
アクティブコンパレータ:Umeå, vitamin D 10 microg/d, light skin
Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
The vitamin D supplement will be provided as a milk drink taken daily.
実験的:Malmö, vitamin D 25 microg/d, dark skin
Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
The vitamin D supplement will be provided as a milk drink taken daily.
実験的:Malmö, vitamin D 25 microg/d, light skin
Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
The vitamin D supplement will be provided as a milk drink taken daily.
アクティブコンパレータ:Malmö, vitamin D 10 microg/d, dark skin
Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
The vitamin D supplement will be provided as a milk drink taken daily.
アクティブコンパレータ:Malmö, vitamin D 10 microg/d, light skin
Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
The vitamin D supplement will be provided as a milk drink taken daily.
プラセボコンパレーター:Malmö, placebo, dark skin,
Participants with dark skin will be randomized to a milk drink without added vitamin D (placebo).
Milk drink with no extra vitamin D (placebo)
他の名前:
  • プラセボ
プラセボコンパレーター:Malmö, placebo, light skin
Participants with light skin will be randomized to a milk drink without added vitamin D (placebo).
Milk drink with no extra vitamin D (placebo)
他の名前:
  • プラセボ
実験的:Umeå, vitamin D 25 microg/d, dark skin
Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
The vitamin D supplement will be provided as a milk drink taken daily.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
Serum 25OH-vitamin D levels
時間枠:90 days after start of treatment
90 days after start of treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
Bone mineralisation
時間枠:120 days after start of treatment
Bone mineralisation will be measured with DXA-scan, serum PTH and serum osteocalcin
120 days after start of treatment

その他の成果指標

結果測定
メジャーの説明
時間枠
Inflammatory and immunological markers
時間枠:90 days after start of treatment
CRP, interleukin (IL) -1 and 2, IL-4, IL-6, I-10, Il-17, CD40 ligand, TNF-alfa, IFNγ, fibrinogen and antisecretory factor
90 days after start of treatment
Behavioral and emotional well-being
時間枠:90 days after start of treatment
Parental assessment using Child Behavioral Checklist
90 days after start of treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Inger Öhlund, Ph.D.、Umeå University
  • スタディチェア:Torbjörn Lind, M.D., Ph.D.、Umeå University
  • スタディチェア:Pia Karlsland-Åkesson, M.D., Ph.D.、University hospital, Malmö/Lund
  • スタディチェア:Sven-Arne Silfverdal, M.D., Ph.D.、Umeå University
  • スタディチェア:Olle Hernell, M.D., Ph.D.、Umeå University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2012年11月1日

一次修了 (実際)

2013年4月1日

研究の完了 (実際)

2013年7月1日

試験登録日

最初に提出

2012年11月26日

QC基準を満たした最初の提出物

2012年11月30日

最初の投稿 (見積もり)

2012年12月4日

学習記録の更新

投稿された最後の更新 (見積もり)

2016年11月1日

QC基準を満たした最後の更新が送信されました

2016年10月31日

最終確認日

2016年10月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する